Last week, 246 members of the House of Representatives, including 35 from California, signed a letter to Health and Human Services Secretary Azar urging him to use his authority to address recent actions taken by pharmaceutical companies that undermine the 340B Drug Pricing Program.
This content is restricted to members.
